Categories Health Care, U.S. Markets News

NASH drug developer Genfit plans $132-million US IPO, to list on Nasdaq

France-based biopharmaceutical firm Genfit (EPA: GNFT) has launched a global offering of its American Depository Shares and ordinary shares to raise around $132 million. The company also intends to list as “GNFT” on the Nasdaq Global Market.

An SEC filing by the company indicated last week that the main purpose of the offering is to take forward the development of the treatment for non-alcoholic steatohepatitis, or NASH, a type of fatty liver disease that is becoming common mainly due to the unhealthy food habits among the people. In the offering, the company intends to issue and sell about five million shares at $26.33 per share to investors. It also plans a private placement of its ordinary shares in Europe and other countries, simultaneously.

Genfit is looking to use $15 million of the proceeds from the offering to prepare for the commercialization of elafibranor, the drug candidate for NASH. Around $50 million will be used for the completion of the phase-III study of elafibranor and the further procedures – up to submission of new drug applications in the US and Europe. The company plans to use around $35 million of the remaining proceeds to initiate and complete the phase-III study of elafibranor for the treatment of primary biliary cholangitis.

An SEC filing by the company indicated last week that the main purpose of the offering is to take forward the development of its NASH drug

It is expected that the global offering and the private placement will close simultaneously on the third trading day after the final pricing and allocation of the offering.

Genfit is specialized in the development of drugs and diagnostic solutions for the treatment of various liver diseases. Elafibranor, the company’s lead drug candidate, has reached the final stages of development for the treatment of NASH, giving it an advantage over rivals. Recently, Genfit received FDA approval for the phase-II clinical trial of elafibranor for non-alcoholic steatohepatitis in children and adolescents.

Also read: Zynerba Pharmaceuticals receives US patent for its CBD gel

Meanwhile, the underwriters for the global offering have been granted a 30-day option to buy additional ADS and ordinary shares valued up to 15% of the total number of shares being offered. Excluding the underwriters’ option to purchase additional shares, the offering is expected to result in the dilution of about 14% of Genfit’s outstanding share capital.

After slipping to a two-year low in the final weeks of last year, Genfit shares have gained more than 40% on the Euronext Paris stock exchange. The stock is currently trading slightly below the levels seen a year earlier.

 

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

HPE Earnings: Hewlett Packard Q1 2024 profit drops but beats Street view

Information technology solutions provider Hewlett Packard Enterprise (NYSE: HPE) on Thursday reported lower earnings and revenues for the first quarter of 2024. Earnings, however, exceeded analysts’ forecasts. First-quarter profit, excluding

After entering FY24 on a high note, Costco is all set to report Q2 results

Costco Wholesale Corporation (NASDAQ: COST) stands out in the retail space for its unique business model that enables the warehouse behemoth to grow store traffic and market share constantly. Currently,

Hormel (HRL) expects continued momentum from its foodservice business in FY2024

Shares of Hormel Foods Corporation (NYSE: HRL) soared over 13% on Thursday after the company delivered better-than-expected earnings results for the first quarter of 2024 and reaffirmed its outlook for

Comments

  1. Pingback: Academic Year
  2. Pingback: attendance
  3. Pingback: Webmaster
  4. Pingback: Fiverr Earn
  5. Pingback: Fiverr Earn
  6. Pingback: Fiverr Earn
  7. Pingback: Fiverr Earn
  8. Pingback: fiverrearn.com
  9. Pingback: fiverrearn.com
  10. Pingback: liv pure
  11. Pingback: TMS System
  12. Pingback: quietum plus buy
  13. Pingback: fiverrearn.com
  14. Pingback: weather tomorrow
  15. Pingback: clima para mañana
  16. Pingback: fiverrearn.com
  17. Pingback: french bulldog
  18. Pingback: fiverrearn.com
  19. Pingback: fluffy frenchies
  20. Pingback: aussiedoodle
  21. Pingback: Yo.fan approval
  22. Pingback: crypto news
  23. Pingback: future university
  24. Pingback: Warranty
  25. Pingback: FUE
  26. Pingback: Interstate moving
  27. Pingback: Classic Books 500
  28. Pingback: FiverrEarn
  29. Pingback: Streamer
  30. Pingback: FiverrEarn
  31. Pingback: OnlyFans Australia
  32. Pingback: partners
  33. Pingback: FiverrEarn
  34. Pingback: FiverrEarn
  35. Pingback: FiverrEarn
  36. Pingback: FiverrEarn
  37. Pingback: FiverrEarn
  38. Pingback: FiverrEarn
  39. Pingback: FiverrEarn
  40. Pingback: FiverrEarn
  41. Pingback: FiverrEarn
  42. Pingback: FiverrEarn
  43. Pingback: FiverrEarn
  44. Pingback: FiverrEarn
  45. Pingback: FiverrEarn
  46. Pingback: Butter
  47. Pingback: christmas
  48. Pingback: Slot Thailand
  49. Pingback: Kuliah Termurah
  50. Pingback: FiverrEarn
  51. Pingback: FiverrEarn
  52. Pingback: cheap sex cams
  53. Pingback: dehydrated water
  54. Pingback: frt trigger
Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top